

**FOR FURTHER INFORMATION CONTACT:** Sandra M. Peay or Renee A. Horton, Contact Representatives, Federal Trade Commission, Premerger Notification Office, Bureau of Competition, Room 303, Washington, D.C. 20580, (202) 326-3100.

By Direction of the Commission.

**Donald S. Clark,**

*Secretary.*

[FR Doc. 95-6752 Filed 3-17-95; 8:45 am]

BILLING CODE 6750-01-M

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Food and Drug Administration

[Docket No. 95N-0069]

#### **Drug Export; Pepcid AC (Famotidine 10 Milligram (mg)) Compressed Chewable Tablets (CCT)**

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice.

**SUMMARY:** The Food and Drug Administration (FDA) is announcing that Merck & Co. has filed an application requesting conditional approval for the export of the human drug Pepcid AC (Famotidine 10 mg) Compressed Chewable Tablets (CCT) to Canada.

**ADDRESSES:** Relevant information on this application may be directed to the Dockets Management Branch (HFA-305), Food and Drug Administration, rm. 1-23, 12420 Parklawn Dr., Rockville, MD 20857, and to the contact person identified below. Any future inquiries concerning the export of human drugs under the Drug Export Amendments Act of 1986 should also be directed to the contact person.

**FOR FURTHER INFORMATION CONTACT:** James E. Hamilton (HFD-310), Center for Drug Evaluation and Research, Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-594-2073.

**SUPPLEMENTARY INFORMATION:** The drug export provisions in section 802 of the Federal Food, Drug, and Cosmetic Act (the act) (21 U.S.C. 382) provide that FDA may approve applications for the export of drugs that are not currently approved in the United States. Section 802(b)(3)(B) of the act sets forth the

requirements that must be met in an application for approval. Section 802(b)(3)(C) of the act requires that the agency review the application within 30 days of its filing to determine whether the requirements of section 802(b)(3)(B) have been satisfied. Section 802(b)(3)(A) of the act requires that the agency publish a notice in the **Federal Register** within 10 days of the filing of an application for export to facilitate public participation in its review of the application. To meet this requirement, the agency is providing notice that Merck & Co., BLA-30, West Point, PA 19486, has filed an application requesting conditional approval for the export of the human drug Pepcid AC (Famotidine 10 mg) Compressed Chewable Tablets (CCT) to Canada. This product is indicated for the treatment and prevention of heartburn. The firm does have new drug application approval for various other dosage forms and strengths of Pepcid. The application was received and filed in the Center for Drug Evaluation and Research on February 17, 1995, which shall be considered the filing date for purposes of the act.

Interested persons may submit relevant information on the application to the Dockets Management Branch (address above) in two copies (except that individuals may submit single copies) and identified with the docket number found in brackets in the heading of this document. These submissions may be seen in the Dockets Management Branch between 9 a.m. and 4 p.m., Monday through Friday.

The agency encourages any person who submits relevant information on the application to do so by March 30, 1995, and to provide an additional copy of the submission directly to the contact person identified above, to facilitate consideration of the information during the 30-day review period.

This notice is issued under the Federal Food, Drug, and Cosmetic Act (sec. 802 (21 U.S.C. 382)) and under authority delegated to the Commissioner of Food and Drugs (21 CFR 5.10) and redelegated to the Center for Drug Evaluation and Research (21 CFR 5.44).

Dated: March 8, 1995.

**Betty L. Jones,**

*Acting Deputy Director, Office of Compliance, Center for Drug Evaluation and Research.*

[FR Doc. 95-6727 Filed 3-17-95; 8:45 am]

BILLING CODE 4160-01-F

## Health Resources and Services Administration

### **Maternal and Child Health Services; Federal Set-Aside Program; Genetic Services and Maternal and Child Improvement Projects for Fiscal Year (FY) 1995: Cancellation of Cycle for Certain Grants and Cooperative Agreements; Extension of Certain Application Deadline Dates**

Notice of Availability of Funds for Special Project Grants and Cooperative Agreements; Maternal and Child Health Services; Federal Set-Aside Program; Genetic Services and Maternal and Child Improvement Projects for fiscal year (FY) 1995, section 502(a), title V of the Social Security Act, was published on February 13, 1995, at 60 FR 8244. Section 4.1.2.1. of this notice announced the availability of funds for 2 grants in the Maternal, Infant, Child and Adolescent Health category priority identified as "Content and Organization of Care for Women of Childbearing Age, Infants, Children, Adolescents, and their Families." Section 4.2.3. of the notice announced the availability of funds for up to four cooperative agreements in the Childhood Injury Prevention category.

Since publication of this notice, it has been determined that amounts allocated for grants under Section 4.1.2.1. are insufficient to permit a competitive grant cycle in the "Content and Organization of Care" priority for FY 1995. As a result, this competition is herewith canceled. Additionally, the Department has decided that it prefers to implement contracts rather than award cooperative agreements in order to acquire the work it wishes to have accomplished by the centers described in the Section 4.2.3. Childhood Injury Prevention category. This competition is also herewith canceled. It is anticipated that contracts for this purpose will be awarded during the second quarter of FY 1996; a request for proposals will be advertised at the appropriate time. To ensure continuity in this activity until then, the cooperative agreements with existing Childhood Injury Prevention centers will be extended for six months, through February 1996.

Two of the deadline dates announced in the February 13, Notice of Availability of Funds for Special Project Grants and Cooperative Agreements; Maternal and Child Health Services; Federal Set-Aside Program; Genetic Services and Maternal and Child Improvement Projects for fiscal year (FY) 1995, are being extended. The deadline date for the remaining grants announced under Section 1.2.1. is hereby extended to May 10, 1995. In